
AI is about to change healthcare. These 25 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
For Hubbell, the core investment story is about a company shifting from being seen as a traditional electrical hardware supplier to a broader grid infrastructure and analytics platform business. The latest quarter reinforced that narrative: higher 2025 sales and earnings, expanding margins, and a regular US$1.42 dividend all point to a business that is executing against its plan. Management’s 2026 guidance for 7% to 9% total sales growth and US$17.30 to US$18.00 in GAAP EPS helps frame near term expectations, even if it landed only modestly above the 2025 outcome and just ahead of analyst assumptions. The launch of Aclara360 and the DMC Power acquisition sharpen the short term catalysts around software, data centers and grid modernization, but they also raise the stakes on integration, capital allocation and execution in higher-value, more complex offerings.
However, one key risk investors should be aware of is how higher-value growth bets could amplify execution missteps. Hubbell's share price has been on the slide but might be up to 33% below fair value. Find out if it's a bargain.Explore 3 other fair value estimates on Hubbell - why the stock might be worth less than half the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
Our daily scans reveal stocks with breakout potential. Don't miss this chance:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com